Professor of Medicine and Surgery Baylor College of Medicine
Gastroenterology
Dr. John M. Vierling, MD
|
|
Give Review
John Vierling is an expert in the field of Gastroenterology. He attended Stanford University School of Medicine. Stanford University School of Medicine is a top medical university. Stanford University School of Medicine has a rank of 2 in research and a 25 in primary care He over the years received 3 awards: "America's Top Doctors", "Top Doctors:SE Texas" and "CMS Meaningful Use Stage 1 Certification". Dr. John M. Vierling is a published doctor and has 44 publications published. The lastest was: 'Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.' He accepts Medicare.
Publications
- Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with Hepatitis C virus genotype 1 infection: a randomized trial.
- Changing nomenclature for PBC: From 'Cirrhosis' to 'cholangitis'.
- Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management.
- Autoimmune Hepatitis.
- Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with Hepatitis C vi...
- Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null Responses to peginterferon/ribavirin.
- The Combination of MK-5172, Peginterferon, and Ribavirin is Effective in Treatment-Naive Patients with Hepatitis C Virus Genotype 1 Infection Without Cirrhosis.
- Long-Term Follow-Up of portopulmonary hypertension patients after Liver Transplantation.
- An overview of emerging therapies for the treatment of chronic Hepatitis C.
- Genetics of Drug-Induced Hepatotoxicity Toxicity in Gilbert's Syndrome.
- Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response.
- HCV RNA viral load assessments in the era of direct-acting antivirals.
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with Hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, mult...
- Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-?2b and ribavirin in patients with chronic Hepatitis C in the SPRINT-1 T...
- Hepatitis C virus viral assays in the direct-acting antiviral era.
- Erratum to: Hepatitis B virus management to prevent reactivation after chemotherapy: a review.
- Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic Hepatitis C genotype 1 infection.
- Hepatitis B virus management to prevent reactivation after chemotherapy: a review.
- Low rates of Hepatitis B virus screening at the onset of chemotherapy.
- Autoimmune Hepatitis and antigen-specific T regulatory cells: when can we send in the regulators?
- HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury.
- Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 Hepatitis C virus infection.
- Hepatitis B and Hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based Hepatitis screening.
- The role of Biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host disease.
- Interaction of CD44 and hyaluronic acid enhances Biliary epithelial proliferation in cholestatic livers.
- The immunology of Hepatitis B.
- Justice, administrative law, and the transplant clinician: the ethical and legislative basis of a national policy on donor liver allocation.
- Treatment of Hepatitis C infection.
- Etiopathogenesis of primary sclerosing cholangitis.
- Management of patients with Cirrhosis in Southern California: results of a practitioner survey.
- Morbidity in live liver donors: standards-based adverse event reporting further refined.
- Future Treatment Options in PBC.
- Management of HBV Infection in Liver Transplantation Patients.
- Imatinib (Gleevec)-induced hepatotoxicity.
- Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury.
- Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel Disease.
- Primary Biliary cirrhosis and autoimmune cholangiopathy.
- The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host.
- 6-thioguanine can cause serious liver injury in inflammatory bowel Disease patients.
- Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome.
- Determinants of early mortality in patients with decompensated chronic Hepatitis B treated with antiviral therapy.
- Evolving new therapies of autoimmune Hepatitis.
Schools
Stanford University
Strong Memorial Hospital
Liver Unit Nih
Uc Med Center
Procedures Preformed
- Liver Biopsy
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- CMS Meaningful Use Stage 1 Certification
Education
-
UCSF -
University of Rochester -
Stanford University School of Medicine
Hospital
-
Baylor St. Luke's Medical Center -
Michael E. DeBakey Veterans Affairs Medical Center
Drug Facts
| NPI NUMBER | 1043390388 | |
| NPPES Provider LastName | VIERLING | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 770302348 | |
| NPPES Provider State | TX | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 183.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1043390388 |
| Last Name Of The Provider | VIERLING |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
Dr. Cole T. Thomson, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Atilla Ertan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rise J. Stribling, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Arturo A. Bravo, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Dang M. Nguyen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kalpesh K. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Narayana P. Narayana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alireza R. Tabrizi, MD |
|
Dr. Gowrappala S. Ramesh, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Harsadbhai D. Patel, MD
This Doctor is OpenDoctor Recommended.
|